Elevance Health Rises 0.19% on $370M Volume (Ranked 289th) as Analysts Split on Legal Setbacks and Valuation Appeal

Elevance Health (ELV) closed on August 28, 2025, with a 0.19% gain, trading at $306.00 after hours. The stock saw a volume of $370 million, ranking 289th in market activity. Analysts highlight a mixed outlook, with 12 "buy" ratings and 6 "hold" ratings, though recent legal setbacks, including a loss in a Medicare Advantage star ratings case, have raised concerns. Despite this, the company’s valuation remains attractive, with a P/E ratio of 13.44, below the healthcare sector average of 31.43.

Short interest in ELV has increased by 4.41% month-over-month, with 1.26% of shares sold short. This aligns with a "days to cover" ratio of 1.2, indicating moderate bearish sentiment. However, the stock’s dividend strength remains a positive, offering a 2.16% yield with 14 consecutive years of growth. Analysts project earnings to rise by 14.99% next year, though the PEG ratio of 1.16 suggests potential overvaluation relative to growth.

Recent developments include a partnership with NACHC to integrate nutrition into care and a legal challenge over Medicare Advantage ratings. These events underscore regulatory and operational risks. Institutional ownership at 89.24% reflects strong confidence, but insider buying activity has yet to offset broader market skepticism. The stock’s performance remains tied to its ability to navigate regulatory pressures and sustain cost-effective growth in a competitive healthcare landscape.

The backtest result indicates a "query limit exceeded" error, highlighting technical constraints in accessing historical data for deeper analysis.